Novel Agents Targeting the Source of HCM Disease


Martin S. Maron, MD
Director, Hypertrophic Cardiomyopathy Center
Co-Director, Cardiac CT and MRI
Assistant Professor, Tufts University School of Medicine, Boston, MA
Martin S. Maron, MD

Dr. Martin Maron is Director of the Hypertrophic Cardiomyopathy Center and Research Institute at Tufts Medical Center and the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center. His research interests are the diagnosis and management of hypertrophic cardiomyopathy including the role of cardiovascular magnetic resonance in assessment of patients with HCM and novel drug therapy to modify the disease. Dr. Maron has co-authored over 200 original publications on HCM including in New England Journal of Medicine, Lancet, Circulation and Journal of the American College of Cardiology.

Harry Rakowski, MD, FRCP, FACC, FASE
Professor of Medicine, University of Toronto
Past Douglas Wigle Research Chair in HCM
Director, Hypertrophic Cardiomyopathy Clinic, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario
Harry Rakowski, MD, FRCP, FACC, FASE

Dr. Rakowski is a senior cardiologist at the Peter Munk Cardiac Centre, and a world-renowned specialist in Hypertrophic Cardiomyopathy. He is a Professor of Medicine at the University of Toronto and has taught hundreds of cardiology residents as a former Director of Clinical Cardiology and former Deputy Director for the Peter Munk Cardiac Centre over his past 40 years of service.

Dr. Rakowski has served as the past Chair of the Royal College of Medicine Cardiology Board exams as well as the President of the American Society of Echocardiography and the National Board of Echocardiography and has been the Chair of the Council of Cardiovascular Organizations. Currently, he is the Director of the Hypertrophic Cardiomyopathy Clinic and its research program. Additionally, he serves as Chair of the Peter Munk Cardiac Centre Innovation Committee. Dr. Rakowski is a widely published prolific scientist and has written many guideline papers that have been instrumental in educating cardiologists internationally.

In addition, over the last 24 months he has taken his clinical knowledge and writing acumen to the public. He has been one of the leading voices on the COVID-19 pandemic in Canada, sharing his thoroughly researched and well-written perspective with readers at many national publications including the National Post,, and at the – a project by the Centre for Civic Engagement run by members of the Munk School for Global Affairs and nationally acclaimed journalists.

Statement of Need

Hypertrophic cardiomyopathy (HCM) is prevalent around the world, with a conservatively estimated 20 million individuals affected. Even in developed countries, current management of HCM is suboptimal. Much has been learned over the past 2 decades about the pathophysiology of HCM and new therapies such as mavacamten, CK-274, IMB-101, and CT-G20 are currently being developed and tested in clinical trials addressing the underlying pathophysiology of HCM. Although these new agents are in late stages of development, clinicians are often not fully up to date on this progress and the potential opportunity to improve care for patients.

Please join Drs. Maron and Rakowski in this final installment of a CMEO Snack series on HCM as they discuss methods to assess study results of emerging HCM disease-specific treatments targeting cardiac myosin in order to optimize outcomes for patients.

Learning Objectives

At the end of this CME/CE activity, participants should be able to assess study results of emerging HCM disease-specific treatments regarding cardiac myosin.

Financial Support

Supported by an educational grant from Bristol Myers Squibb.

Target Audience

Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Pharmacists/Pharmacy Tech (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Through a mutual recognition agreement between the AMA and the UEMS-EACCME®, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

Dr. Maron reports the following financial relationships:

Advisory Board: Cytokenetics (REDWOOD-HCM Steering Committee)

Consultant: Imbria and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Rakowski has no financial relationships to disclose.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Warren Beckman (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

Novel Agents Targeting the Source of HCM Disease
Event Date: 04/20/2022